BCR and mantle cell lymphoma: A preclinical study evaluated the combination of ibrutinib and idelalisib in MCL and CLL, since both drugs target BCR signaling via different mechanisms, and found that together, the two agents showed more effective inhibition of BCR-controlled adhesion than either agent alone, supporting clinical study of these drugs in combination in B-cell malignancies [92].